Use of rituximab in diffuse large B-cell lymphoma in the salvage setting

British Journal of Haematology

Volumn 143, Issue 5, 2008, Pages 607-621

  Gisselbrecht, Christian ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Aggressive; Diffuse large B cell lymphoma; Non Hodgkin lymphoma; Rituximab; Salvage

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ENZASTAURIN; EPIRUBICIN; EPRATUZUMAB; ETOPOSIDE; GALLIUM NITRATE; GEMCITABINE; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; METHYLPREDNISOLONE; MITOGUAZONE; MITOXANTRONE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PREDNISOLONE; PREDNISONE; RITUXIMAB; TENIPOSIDE; TOPOTECAN; VINCRISTINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTINUOUS INFUSION; HUMAN; LARGE CELL LYMPHOMA; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; REVIEW; SALVAGE THERAPY; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; PREDNISONE; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; VINCRISTINE;

EID: 55949128237     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07383.x     Document Type: Review

References (96)

1. Arnold, C., Cuthbert, R., Morris, T.C.M., Kettle, P., Jones, F. Drake, M. (2005) Rituximab-ESHAP as salvage therapy in relapsed aggressive B cell lymphoma. Haematologica, 90 (Suppl. 1 (Abstract 1146).
2. Aydin, S., Duhrsen, U. Nuckel, H. (2007) Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients. Annals of Hematology, 86, 271 276.
3. Baldissera, R.C., Nucci, M., Vigorito, A.C., Maiolino, A., Simoes, B.P., Lorand-Metze, I., Aranha, F.J., Miranda, E.C., Pagnano, K.B., Ruiz, M.A., Moraes, A.A. De Souza, C.A. (2006) Frontline therapy with early intensification and autologous stem cell transplantation versus conventional chemotherapy in unselected high-risk, aggressive non-Hodgkin's lymphoma patients: a prospective randomized GEMOH report. Acta Haematologica, 115, 15 21.
4. Betticher, D.C., Martinelli, G., Radford, J.A., Kaufmann, M., Dyer, M.J., Kaiser, U., Aulitzky, W.E., Beck, J., von Rohr, A., Kovascovics, T., Cogliatti, S.B., Cina, S., Maibach, R., Cerny, T. Linch, D.C. (2006) Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL). Annals of Oncology, 17, 1546 1552.
5. Bieker, R., Kessler, T., Berdel, W.E. Mesters, R.M. (2003) Rituximab in combination with platinum-containing chemotherapy in patients with relapsed or primary refractory diffuse large B-cell lymphoma. Oncology Reports, 10, 1915 1917.
6. Blay, J., Gomez, F., Sebban, C., Bachelot, T., Biron, P., Guglielmi, C., Hagenbeek, A., Somers, R., Chauvin, F. Philip, T. (1998) The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood, 92, 3562 3568.
7. Borgerding, A., Hasenkamp, J., Chapuy, B., Truemper, L., Wulf, G. Glass, B. (2006) Response to re-treatment with rituximab plus salvage-chemotherapy in refractory or relapsed aggressive non-Hodgkin's lymphoma. Blood, 108, 262b (Abstract 4720).
8. Bosly, A., Coiffier, B., Gisselbrecht, C., Tilly, H., Auzanneau, G., Andrien, F., Herbrecht, R., Legros, M., Devaux, Y. Jaubert, J. (1992) Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen. Journal of Clinical Oncology, 10, 1615 1623.
9. Cabanillas, F., Hagemeister, F.B., McLaughlin, P., Velasquez, W.S., Riggs, S., Fuller, L. Smith, T. (1987) Results of MIME salvage regimen for recurrent or refractory lymphoma. Journal of Clinical Oncology, 5, 407 412.
10. Cabanillas, F., Velasquez, W.S., McLaughlin, P., Jagannath, S., Hagemeister, F.B., Redman, J.R., Swan, F. Rodriguez, M.A. (1988) Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease. Seminars in Hematology, 25, 47 50.
11. Cabanillas, F., Liboy, I., Rodriguez-Monge, E., Pavia, O., Robles, N., Maldonado, N., Rivera, E. Suau, L. (2006) A dose dense low toxicity salvage regimen for histologically aggressive non-Hodgkin's lymphoma (NHL): gemcitabine, rituximab, oxaliplatin combination (GROC) plus pegfilgrastim. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings, 24, (Abstract 17513).
12. Canales, M., Sanjurjo, M., Garcia-Vela, J., de Paz, R., Lopez de la Guia, A., Martin, M., Hernadez, D. Hernandez-Navarro, F. (2005) Paclitaxel and topotecan in combination with rituximab as effective second-line salvage regimen in resistant aggressive non-Hodgkin's lymphoma. Annals of Oncology, 16 (Suppl. 5 v181 (Abstract 494).
13. Chiesa, C., Botta, F., Di Betta, E., Coliva, A., Maccauro, M., Aliberti, G., Bavusi, S., Devizzi, L., Guidetti, A., Seregni, E., Gianni, A.M. Bombardieri, E. (2007) Dosimetry in myeloablative (90)Y-labeled ibritumomab tiuxetan therapy: possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary results. Cancer Biotherapy & Radiopharmaceuticals, 22, 113 120.
14. Cilley, J. Winter, J.N. (2006) Radioimmunotherapy and autologous stem cell transplantation for the treatment of B-cell lymphomas. Haematologica, 91, 114 120.
15. Coiffier, B. (2003) Immunochemotherapy: the new standard in aggressive non-Hodgkin's lymphoma in the elderly. Seminars in Oncology, 30, 21 27.
16. Coiffier, B. (2006) Monoclonal antibody as therapy for malignant lymphomas. Comptes Rendus Biologies, 329, 241 254.
17. Coiffier, B., Haioun, C., Ketterer, N., Engert, A., Tilly, H., Ma, D., Johnson, P., Lister, A., Feuring-Buske, M., Radford, J.A., Capdeville, R., Diehl, V. Reyes, F. (1998) Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood, 92, 1927 1932.
18. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 235 242.
19. Coiffier, B., Feugier, P., Mounier, N., Franchi-Rezgui, P., Van Den Neste, E., Macro, M., Haioun, C., Sebban, C., Bordessoule, D. Tilly, H. (2007) Long-term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older patients with diffuse large B-cell lymphoma show good survival in poor-risk patients. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings, 26, 443s (Abstract 8009).
20. Corazzelli, G., Russo, F., Capobianco, G., Marcacci, G., Della Cioppa, P. Pinto, A. (2006) Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study. Annals of Oncology, 17 (Suppl. 4 iv18 iv24.
21. Crump, M., Shepherd, L. Lin, B. (2005) A randomized phase III study of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin as salvage chemotherapy followed by posttransplantation rituximab maintenance therapy versus observation for treatment of aggressive B-cell and T-cell non-Hodgkin's lymphoma. Clinical Lymphoma, 6, 56 60.
22. Cuttica, A., Zallio, F., Ladetto, M., Di Nicola, M., Caracciolo, D., Magni, M., Marinone, C., Dell'Aquila, M., Rosace, M., Pileri, A., Boccadoro, M., Gianni, A.M. Tarella, C. (2003) Patients with high-risk aggressive lymphoma treated with frontline intensive chemotherapy and autografting: evidence of marked differences in outcome between patients with age-adjusted International Prognostic Index scores 2 and 3. Cancer, 98, 983 992.
23. El Gnaoui, T., Dupuis, J., Belhadj, K., Jais, J.P., Rahmouni, A., Copie-Bergman, C., Gaillard, I., Diviné, M., Tabah-Fisch, I., Reyes, F. Haioun, C. (2007) Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Annals of Oncology, 18, 1363 1368.
24. Feugier, P., Van Hoof, A., Sebban, C., Solal-Celigny, P., Bouabdallah, R., Ferme, C., Christian, B., Lepage, E., Tilly, H., Morschhauser, F., Gaulard, P., Salles, G., Bosly, A., Gisselbrecht, C., Reyes, F. Coiffier, B. (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. Journal of Clinical Oncology, 23, 4117 4126.
25. Fisher, R.I., Gaynor, E.R., Dahlberg, S., Oken, M.M., Grogan, T.M., Mize, E.M., Glick, J.H., Coltman, Jr., C.A. Miller, T.P. (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New England Journal of Medicine, 328, 1002 1006.
26. Flohr, T., Hess, G., Kolbe, K., Gamm, H., Nolte, H., Stanislawski, T., Huber, C. Derigs, H.G. (2002) Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL. Bone Marrow Transplantation, 29, 769 775.
27. Gianni, A.M., Berinstein, N.L., Evans, P.A., Lopez-Guillermo, A. Solano, C. (2002) Stem-cell transplantation in non-Hodgkin's lymphoma: improving outcome. Anti-Cancer Drugs, 13 (Suppl. 2 S35 S42.
28. Gisselbrecht, C. Mounier, N. (2003) Rituximab: enhancing outcome of autologous stem cell transplantation in non-Hodgkin's lymphoma. Seminars in Oncology, 30, 28 33.
29. Gisselbrecht, C. Mounier, N. (2004) Improving second-line therapy in aggressive non-Hodgkin's lymphoma. Seminars in Oncology, 31, 12 16.
30. Gisselbrecht, C. Mounier, N. (2006) Managing large cell lymphoma. Annals of Oncology, 17 (Suppl. 4 iv8 iv11.
31. Gisselbrecht, C., Lepage, E., Molina, T., Quesnel, B., Fillet, G., Lederlin, P., Coiffier, B., Tilly, H., Gabarre, J., Guilmin, F., Hermine, O. Reyes, F. (2002) Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. Journal of Clinical Oncology, 20, 2472 2479.
32. Gisselbrecht, C., Schmitz, N., Mounier, N., Ma, D., Trneny, M., Hagberg, H., Linch, D.C., Shpilberg, O., Ketterer, N., Glass, B., Bosly, A., Gill, D., Gaulard, P. Moskowitz, C. (2007a) R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by stem cell transplantation and maintenance treatment with rituximab or not: first interim analysis on 200 patients. CORAL Study. Blood, 110, 159a (Abstract 517).
33. Gisselbrecht, C., Bethge, W., Duarte, R.F., Gianni, A.M., Glass, B., Haioun, C., Martinelli, G., Nagler, A., Pettengell, R., Sureda, A., Tilly, H. Wilson, K. (2007b) Current status and future perspectives for yttrium-90 ((90)Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplantation, 40, 1007 1017.
34. Guglielmi, C., Gomez, F., Philip, T., Hagenbeek, A., Martelli, M., Sebban, C., Milpied, N., Bron, D., Cahn, J.Y., Somers, R., Sonneveld, P., Gisselbrecht, C., Van Der Lelie, H. Chauvin, F. (1998) Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. Journal of Clinical Oncology, 16, 3264 3269.
35. Gutierrez, M., Chabner, B.A., Pearson, D., Steinberg, S.M., Jaffe, E.S., Cheson, B.D., Fojo, A. Wilson, W.H. (2000) Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. Journal of Clinical Oncology, 18, 3633 3642.
36. Habermann, T.M., Weller, E.A., Morrison, V.A., Gascoyne, R.D., Cassileth, P.A., Cohn, J.B., Dakhil, S.R., Woda, B., Fisher, R.I., Peterson, B.A. Horning, S.J. (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. Journal of Clinical Oncology, 24, 3121 3127.
37. Haioun, C., Lepage, E., Gisselbrecht, C., Salles, G., Coiffier, B., Brice, P., Bosly, A., Morel, P., Nouvel, C., Tilly, H., Lederlin, P., Sebban, C., Briere, J., Gaulard, P. Reyes, F. (2000) Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol - a groupe d'Etude des lymphomes de l'Adulte study. Journal of Clinical Oncology, 18, 3025 3030.
38. Haioun, C., Mounier, N., Emile, J.F., Bologna, S., Coiffier, B., Tilly, H., Recher, C., Fermé, C., Morschhauser, F. Gisselbrecht, C. (2007) Rituximab compared to observation after high-dose consolidative first-line chemotherapy (HDC) with autologous stem cell transplantation in poor-risk diffuse large B-cell lymphoma: updated results of the LNH98-B3 GELA study. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings, 25, (Abstract 8012).
39. Han, L.N., Zhou, J., Hirose, T., Imai, Y., Ishiguro, T. Chou, T. (2006) Feasibility and efficacy of high-dose melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED) chemotherapy with or without rituximab followed by autologous stem cell transplantation for aggressive and relapsed non-Hodgkin's lymphoma. International Journal of Hematology, 84, 174 181.
40. Herishanu, Y., Terstman, S., Perri, C., Gipstein, L., Ben-Tal, O., Polliack, A. Naparstek, E. (2005) The combination of rituximab, etoposide, ifosfamide and carboplatin (RICE) is safe and effective salvage therapy for elderly patients with aggressive non-Hodgkin's lymphoma. Haematologica, 90 (Suppl. 1 Abstract 999).
41. Hess, G., Flohr, T., Kolbe, K., Bonn, S., Schuler, M., Derigs, H.G. Huber, C. (2006) Effect of rituximab on the long-term outcome after high-dose therapy for relapsed B-cell non-Hodgkin's lymphoma. Annals of Hematology, 85, 769 779.
42. Hicks, L., Buckstein, R., Mangel, J., Piliotis, E., Imrie, K., Cheung, M.C., Spaner, D.E., Reis, M.D., Ghorab, Z., Milliken, V., Pennell, N. Berinstein, N. (2006) Rituximab increases response to ESHAP in relapsed, refractory, and transformed aggressive B-cell lymphoma. Blood, 108, (Abstract 3067).
43. Hochster, H.S., Weller, E., Gascoyne, R.D., Ryan, T.S., Habermann, T.M., Gordon, L.I., Frankel, S. Horning, S. (2007) Cyclophosphamide and fludarabine (CF) in advanced indolent lymphoma: results from the ECOG/CALGB intergroup E1496 trial. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings, 25 Abstract 8004).
44. Horwitz, S.M., Negrin, R.S., Blume, K.G., Breslin, S., Stuart, M.J., Stockerl-Goldstein, K.E., Johnston, L.J., Wong, R.M., Shizuru, J.A. Horning, S.J. (2004) Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood, 103, 777 783.
45. van Imhoff, G.W., van der Holt, B., Mackenzie, M.A., Van't Veer, M.B., Wijermans, P.W., Ossenkoppele, G.J., Schouten, H.C., Sonneveld, P., Steijaert, M.M., Kluin, P.M., Kluin-Nelemans, H.C. Verdonck, L.F. (2005) Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40. Journal of Clinical Oncology, 23, 3793 3801.
46. Jermann, M., Jost, L.M., Taverna, C., Jacky, E., Honegger, H.P., Betticher, D.C., Egli, F., Kroner, T. Stahel, R.A. (2004) Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Annals of Oncology, 15, 511 516.
47. Josting, A., Sieniawski, M., Glossmann, J.P., Staak, O., Nogova, L., Peters, N., Mapara, M., Dorken, B., Ko, Y., Metzner, B., Kisro, J., Diehl, V. Engert, A. (2005) High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. Annals of Oncology, 16, 1359 1365.
48. Kennedy, G.A., Tey, S.K., Cobcroft, R., Marlton, P., Cull, G., Grimmett, K., Thomson, D. Gill, D. (2002) Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review. British Journal of Haematology, 119, 412 416.
49. Kewalramani, T., Zelenetz, A.D., Nimer, S.D., Portlock, C., Straus, D., Noy, A., O'Connor, O., Filippa, D.A., Teruya-Feldstein, J., Gencarelli, A., Qin, J., Waxman, A., Yahalom, J. Moskowitz, C.H. (2004) Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood, 103, 3684 3688.
50. Khouri, I.F., Saliba, R.M., Hosing, C., Okoroji, G.J., Acholonu, S., Anderlini, P., Couriel, D., De Lima, M., Donato, M.L., Fayad, L., Giralt, S., Jones, R., Korbling, M., Maadani, F., Manning, J.T., Pro, B., Shpall, E., Younes, A., McLaughlin, P. Champlin, R.E. (2005) Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. Journal of Clinical Oncology, 23, 2240 2247.
51. Krishnan, A., Nademanee, A., Fung, H.C., Raubitschek, A.A., Molina, A., Yamauchi, D., Rodriguez, R., Spielberger, R.T., Falk, P., Palmer, J.M. Forman, S.J. (2008) Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. Journal of Clinical Oncology, 26, 90 95.
52. Leonard, J.P., Coleman, M., Ketas, J., Ashe, M., Fiore, J.M., Furman, R.R., Niesvizky, R., Shore, T., Chadburn, A., Horne, H., Kovacs, J., Ding, C.L., Wegener, W.A., Horak, I.D. Goldenberg, D.M. (2005) Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. Journal of Clinical Oncology, 23, 5044 5051.
53. Lossos, I.S. (2005) Molecular pathogenesis of diffuse large B-cell lymphoma. Journal of Clinical Oncology, 23, 6351 6357.
54. Mey, U.J., Orlopp, K.S., Flieger, D., Strehl, J.W., Ho, A.D., Hensel, M., Bopp, C., Gorschluter, M., Wilhelm, M., Birkmann, J., Kaiser, U., Neubauer, A., Florschutz, A., Rabe, C., Hahn, C., Glasmacher, A.G. Schmidt-Wolf, I.G. (2006a) Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Cancer Investigation, 24, 593 600.
55. Mey, U.J., Olivieri, A., Orlopp, K.S., Rabe, C., Strehl, J.W., Gorschlueter, M., Hensel, M., Flieger, D., Glasmacher, A.G. Schmidt-Wolf, I.G. (2006b) DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis. Leukemia & Lymphoma, 47, 2558 2566.
56. Moskowitz, C. (2002) Risk-adapted therapy for relapsed and refractory lymphoma using ICE chemotherapy. Cancer Chemotherapy and Pharmacology, 49 (Suppl. 1 S9 S12.
57. Moskowitz, C.H., Bertino, J.R., Glassman, J.R., Hedrick, E.E., Hunte, S., Coady-Lyons, N., Agus, D.B., Goy, A., Jurcic, J., Noy, A., O'Brien, J., Portlock, C.S., Straus, D.S., Childs, B., Frank, R., Yahalom, J., Filippa, D., Louie, D., Nimer, S.D. Zelenetz, A.D. (1999) Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. Journal of Clinical Oncology, 17, 3776 3785.
58. Nadler, L.M., Ritz, J., Hardy, R., Pesando, J.M., Schlossman, S.F. Stashenko, P. (1981) A unique cell surface antigen identifying lymphoid malignancies of B cell origin. Journal of Clinical Investigation, 67, 134 140.
59. Niitsu, N., Kohuri, M., Higashihara, M. Bessho, M. (2006) Phase II study of the CPT-11, mitoxantrone and dexamethasone regimen in combination with rituximab in elderly patients with relapsed diffuse large B-cell lymphoma. Cancer Science, 97, 933 937.
60. Obrtlikova, P.O., Vackova, B., Pytlik, R., Krejcova, H., Klener, P. Trneny, M. (2006) Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for diffuse large B-cell lymphoma. Haematologica, 91 (Suppl. 1 (Abstract 217).
61. Olivieri, A., Santini, G., Patti, C., Chisesi, T., De Souza, C., Rubagotti, A., Aversa, S., Billio, A., Porcellini, A., Candela, M., Centurioni, R., Congiu, A.M., Brunori, M., Nati, S., Spriano, M., Vimercati, R., Marino, G., Contu, A., Tedeschi, L., Majolino, I., Crugnola, M. Sertoli, M.R. (2005a) Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG. Annals of Oncology, 16, 1941 1948.
62. Olivieri, A., Lucesole, M., Capelli, D., Gini, G., Montanari, M., Candela, M., Troiani, E., Scortechini, I., Poloni, A. Leoni, P. (2005b) A new schedule of CHOP/rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation. Biology of Blood and Marrow Transplantation, 11, 627 636.
63. Palacios, A., Naverette, M., Gallur, L., Zuazu, J. Barrenetxea, C. (2006) Re-treatment with rituximab plus chemotherapy in patients with aggressive lymphoma treated previously with CHOP or CHOP-like combinations plus rituximab. Blood, 108 Abstract 4707).
64. Pan, D., Moskowitz, C.H., Zelenetz, A.D., Straus, D., Kewalaramani, T., Noy, A., Qin, J., Teruya-Feldstein, J. Portlock, C.S. (2002) Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation. Cancer Journal, 8, 371 376.
65. Panovska-Stavridis, I., Georgievski, B., Cevreska, L., Stojanovik, A., Siljanovski, N., Ivanovski, M., Hadzi-Pecova, L. Pivkova, A. (2004) Rituximab plus ICE regimen for relapsed and refractory aggressive non-Hodgkin lymphomas. Haematologica, 89 (Suppl. 1 Abstract 763).
66. Pfreundschuh, M., Trumper, L., Kloess, M., Schmits, R., Feller, A.C., Rube, C., Rudolph, C., Reiser, M., Hossfeld, D.K., Eimermacher, H., Hasenclever, D., Schmitz, N. Loeffler, M. (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood, 104, 634 641.
67. Plantier-Colcher, I., Dupriez, B., Simon, M., Detourmignies, L., Jouet, J.P., Fenaux, P., Bauters, F. Morel, P. (1999) The VIM3-AraC regimen followed by autologous stem cell transplantation in refractory or relapsing aggressive non-Hodgkin's lymphoma. A prospective study of 71 consecutive cases. Leukemia, 13, 282 288.
68. Press, O.W., Farr, A.G., Borroz, K.I., Anderson, S.K. Martin, P.J. (1989) Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Research, 49, 4906 4912.
69. Rapoport, A.P., Meisenberg, B., Sarkodee-Adoo, C., Fassas, A., Frankel, S.R., Mookerjee, B., Takebe, N., Fenton, R., Heyman, M., Badros, A., Kennedy, A., Jacobs, M., Hudes, R., Ruehle, K., Smith, R., Kight, L., Chambers, S., MacFadden, M., Cottler-Fox, M., Chen, T., Phillips, G. Tricot, G. (2002) Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy. Bone Marrow Transplantation, 29, 303 312.
70. Rodriguez, M.A., Cabanillas, F.C., Velasquez, W., Hagemeister, F.B., McLaughlin, P., Swan, F. Romaguera, J.E. (1995) Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. Journal of Clinical Oncology, 13, 1734 1741.
71. Rothe, A., Schulz, H., Elter, T., Engert, A. Reiser, M. (2004) Rituximab monotherapy is effective in patients with poor risk refractory aggressive non-Hodgkin's lymphoma. Haematologica, 89, 875 876.
72. Rupolo, M., Spina, M., Michieli, M., Berrata, M., Abbruzzese, L., Mazzucato, M., Gattei, V. Tirelli, U. (2004) R-DHAOX as salvage regimen in patients (pts) with relapsed/resistant non-Hodgkins Lymphoma (NHL). Blood, 104 Abstract 1323).
73. Seyfarth, B., Josting, A., Dreyling, M. Schmitz, N. (2006) Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease. British Journal of Haematology, 133, 3 18.
74. Shimoni, A., Zwass, T., Oksman, Y., Hardan, I., Shem-Tov, N., Yerushalmi, R., Avigdor, A., Ben-Bassat, I. Nagler, A. (2006) Ibritumomab tiuxetan (Zevalin) followed by high-dose chemotherapy and autologous stem-cell transplantation results in improved survival of patients with chemo-refractory non-Hodgkin's lymphoma expected to have poor outcome with standard pre-transplant conditioning. Blood, 108 Abstract 3052).
75. Shimoni, A., Zwas, S.T., Oksman, Y., Hardan, I., Shem-Tov, N., Yerushalmi, R., Avigdor, A., Ben-Bassat, I. Nagler, A. (2007) Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma. Experimental Hematology, 35, 534 540.
76. Shrestha, S., Johnson, C., Jain, S., Patel, D.V. Mehrotra, B. (2004) ESHAP+/- rituximab as salvage therapy for relapsed lymphoma prior to stem cell transplant: single institution experience. Blood, 104 Abstract 4601).
77. Sieniawski, M., Staak, O., Glossmann, J.P., Reineke, T., Scheuss, H., Diehl, V., Engert, A. Josting, A. (2007) Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma. Annals of Hematology, 86, 107 115.
78. Smith, M.R., Joshi, I., Jin, F. Obasaju, C. (2005) Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in SCID mice. BMC Cancer, 5, 103.
79. Smith, S., Toor, A., Klein, J., Rodriguez, T. Stiff, P.J. (2006) The combination of gallium nitrate, rituximab and dexamethasone is effective and safe as a salvage regimen for diffuse large B-cell lymphoma. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings, 24 Abstract 17510).
80. Stamatoullas, A., Fruchart, C., Bastit, D., Boulet, D., Moncondult, M., Piguet, H. Tilly, H. (1996) Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. Cancer, 77, 2302 2307.
81. Strauss, S.J., Morschhauser, F., Rech, J., Repp, R., Solal-Celigny, P., Zinzani, P.L., Engert, A., Coiffier, B., Hoelzer, D.F., Wegener, W.A., Teoh, N.K., Goldenberg, D.M. Lister, T.A. (2006) Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. Journal of Clinical Oncology, 24, 3880 3886.
82. Sweetenham, J.W. (2005) Diffuse large B-cell lymphoma: risk stratification and management of relapsed disease. Hematology/the Education Program of the American Society of Hematology, 1, 252 259.
83. Tarella, C., Zanni, M., Magni, M., Benedetti, F., Barbui, T., Boccadoro, M., Patti, K., Ciceri, F., Gallamini, A., Cortelazzo, S., Zoli, V., Mirto, S., Passera, R., Corradini, P., Pizzolo, G., Gianni, A.M. Rambaldi, A. (2006) Benefit of rituximab addition to high-dose programs with autograft for B-cell lymphoma: a multicenter GITIL survey on 957 patients. Blood, 108 Abstract 207).
84. Tilly, H., Lepage, E., Coiffier, B., Blanc, M., Herbrecht, R., Bosly, A., Attal, M., Fillet, G., Guettier, C., Molina, T.J., Gisselbrecht, C. Reyes, F. (2003) Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood, 102, 4284 4289.
85. Tobinai, K., Igarashi, T., Itoh, K., Kobayashi, Y., Taniwaki, M., Ogura, M., Kinoshita, T., Hotta, T., Aikawa, K., Tsushita, K., Hiraoka, A., Matsuno, Y., Nakamura, S., Mori, S. Ohashi, Y. (2004) Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Annals of Oncology, 15, 821 830.
86. Van Oers, M.H.J., Klasa, R., Marcus, R., Wolf, M., Kimby, E., Gascoyne, R.D., Jack, A., Van't Veer, M.B., Vranovsky, A., Holte, H., van Glabbeke, M., Teodorovic, I., Rozewicz, C. Hagenbeek, A. (2006) Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood, 108, 3295 3301.
87. Velasquez, W.S., Cabanillas, F., Salvador, P., McLaughlin, P., Fridrik, M., Tucker, S., Jagannath, S., Hagemeister, F.B., Redman, J.R. Swan, F. (1988) Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood, 71, 117 122.
88. Velasquez, W.S., McLaughlin, P., Tucker, S., Hagemeister, F.B., Swan, F., Rodriguez, M.A., Romaguera, J., Rubenstein, E. Cabanillas, F. (1994) ESHAP - an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. Journal of Clinical Oncology, 12, 1169 1176.
89. Vellenga, E., van Putten, W.L., van 't Veer, M., Zijlstra, J., Fibbe, W.E., van Oers, R., van Imhoff, G.W., Lugtenburg, E. Huijgens, P.C. (2008) Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL. A prospective randomized HOVON trial. Blood, 111, 537 543.
90. Venugopal, P., Gregory, S.A., Showel, J., Shammo, J., Enschede, S., Larson, M., O'Brien, T., Sokolovsky, T.D. Means, A. (2004) Rituximab (Rituxan) combined with ESHAP chemotherapy is highly active in relapsed/refractory aggressive non-Hodgkin's lymphoma. Blood, 104 Abstract 4636).
91. Wenger, C., Stern, M., Herrmann, R., Rochlitz, C. Pless, M. (2005) Rituximab plus gemcitabine: a therapeutic option for elderly or frail patients with aggressive non Hodgkin's lymphoma? Leukemia & Lymphoma, 46, 71 75.
92. ®; 90YZ) doses calculated to deliver up to 1500 cGy to critical organs may be safely combined with high-dose BEAM and autotransplant in NHL. Blood, 108 Abstract 330).
93. Woehrer, S., Hejna, M., Skrabs, C., Drach, J., Zielinski, C.C., Jaeger, U. Raderer, M. (2005) Rituximab, Ara-C, dexamethasone and oxaliplatin is safe and active in heavily pretreated patients with diffuse large B-cell lymphoma. Oncology, 69, 499 502.
94. Younes, A., McLaughlin, P., Romaguera, J., Hagemeijer, A., Pro, B., Dang, N., Samaniego, F., Rodriguez, J. Fayad, L. (2005) Paclitaxel plus topotecan plus rituximab (TTR): an effective salvage program for the treatment of patients with relapsed/refractory aggressive B-cell non Hodgkin's lymphoma. Annals of Oncology, 16 (Suppl. 5 v101 (Abstract 220).
95. Zelenetz, A.D., Hamlin, P., Kewalramani, T., Yahalom, J., Nimer, S. Moskowitz, C.H. (2003) Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. Annals of Oncology, 14 (Suppl. 1 i5 i10.
96. Zinzani, P.L., Tani, M., Molinari, A.L., Stefoni, V., Zuffa, E., Alinari, L., Gabriele, A., Bonifazi, F., Salvucci, M., Tura, S. Baccarani, M. (2002) Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients. Haematologica, 87, 816 821.